Abemaciclib 150 MG by mouth twice daily for Prostate Cancer
This study is evaluating whether a drug may help reduce the risk of cancer returning in individuals who have already received radiation therapy.
See full descriptionAbout the trial for Prostate Cancer
Treatment Groups
This trial involves 2 different treatments. Abemaciclib 150 MG By Mouth Twice Daily is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for male patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Abemaciclib 150 MG by mouth twice daily will improve 1 primary outcome and 2 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to 3 months of treatment.
Who is running the study
Principal InvestigatorPatient Q & A Section
What are the signs of prostate cancer?
The current study presents a new set of signs of PCa with a large effect size that deserves more attention in both clinicians and researchers in order to improve the detection of prostate cancers.
How many people get prostate cancer a year in the United States?
About 14,400 men will have prostate cancer in their lifetimes, but only 2,700 will succumb to it. Prostate cancer is on the rise in the United States.
Can prostate cancer be cured?
There was no correlation between patient age (mean age: 51.5 yr) or biopsy Gleason score (mean 7.2) and prostate cancer-specific mortality; only the serum PSA level at diagnosis was a significant predictor of prostate cancer-specific mortality.
What causes prostate cancer?
Risk factors for prostate cancer include age, genetics and diet. However, these risks are not completely known, and prostate cancer is caused by random genetic mutations. The effects of aging on prostate cancer development are complex and not fully understood.
What is prostate cancer?
Prostate cancer is the third-most common cancer in men and accounts for 8% of all cancers in men. It is a disease of the male genital system. It is the second-leading cause of cancer mortality (cancer deaths) among men, following lung cancer. The prostate is an organ of the male reproductive system and forms part of the lower urinary tract.\n
What are common treatments for prostate cancer?
The treatment options for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), as listed by the National Comprehensive Cancer Network are summarized here, although additional treatment options exist for prostate cancer that has metastasized. The most commonly recommended treatment options for stage I-IIa prostate cancer are external-beam radiation therapy, hormonal therapy, and external beam radiation therapy combined with pelvic lymph node dissection. For those with either T3 or T4 prostate cancer there are a variety of suggested treatment options; however, it is recommended that patients discuss treatment options with their clinician. The overall 5-year survival rate for prostate cancer is 80-90%. The National Comprehensive Cancer Network lists several treatment options for those who have either locally recurrent prostate cancer or have metastatic disease.
How serious can prostate cancer be?
The seriousness of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) can vary among different patients and also among different geographic regions. The probability of dying from prostate cancer increases from 15% to 36% if the cancer escapes treatment during the early stage of the disease.
What does radiation therapy usually treat?
Radiation therapy is commonly given to men with LUTS or lower urinary tract cancers with the hope of improving symptoms. Yet some patients also have good outcomes with radiation therapy in terms of the risk of recurrence of their disease.
What is the survival rate for prostate cancer?
The survival for prostate cancer patients depends on the stage at diagnosis, aggressiveness of the disease, surgical resectability, age, Gleason score, seminal vesicle extension, race, and hormonal therapy. Prostate cancer is curable in about half of all patients and it seems that prostate cancer can be controlled in most patients when properly treated. Men with Stage T1 prostate cancer are at high risk for early death from the disease, whereas those with Stage T4 prostate cancer have a very high risk for death from metastatic disease. Women of all ages usually have a much higher mortality from prostate cancer.
How quickly does prostate cancer spread?
Despite our efforts, we were limited by the paucity of data on the long-term oncologic status of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in this group of patients. However, the overall rate of metastasis was lower than in other series. This demonstrates a favorable outlook for men treated with radical prostatectomy alone.
Have there been other clinical trials involving radiation therapy?
The combination of surgery and radiation therapy in the management of prostate cancer has not had a role in the past and therefore should not be considered.
What is the average age someone gets prostate cancer?
The average age at diagnosis in the West is 67.8. In Australia the average age at diagnosis is 65.1, and in Scotland was 65.8 for men less than 70.